Slingshot members are tracking this event:
Phase 2a data of Global Blood Therapeutics's(GBT) GBT440 in Hypoxemia in patients with idiopathic pulmonary fibrosis (IPF) who are on supplemental oxygen at rest expected Q4 2017
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
|GBT||Community voting in process|
Slingshot Insights Explained
Oct 23, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 2a, Gbt440, Hypoxemia, Idiopathic Pulmonary Fibrosis